Unlike the documented tumor suppressor role of ERβ in breast, prostate, ovarian, renal and thyroid cancer [50], reports of ERβ action in lung cancer have been controversial [51], with several groups supporting an oncogenic function of the receptor [52–58]. Here, ESR2 is linked to lung cancer.